{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T17:29:47Z","timestamp":1775064587209,"version":"3.50.1"},"reference-count":48,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.clinthera.2024.01.003","type":"journal-article","created":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T14:48:44Z","timestamp":1707922124000},"page":"275-284","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Therapeutic Effect and Side Effects of Pharmacotherapy in Patients With Parkinson Disease and Myasthenia Gravis: A Systematic Review of Case Reports and Case Series Studies"],"prefix":"10.1016","volume":"46","author":[{"given":"Haoyu","family":"Xie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yadi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cindy","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7792-9764","authenticated-orcid":false,"given":"Jung Hung","family":"Chien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuhuai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2024.01.003_bib0001","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1002\/mds.27372","article-title":"International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease","volume":"33","author":"Fox","year":"2018","journal-title":"Mov Disord"},{"key":"10.1016\/j.clinthera.2024.01.003_bib0002","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2021.776847","article-title":"Global trends in the incidence, prevalence, and years lived with disability of Parkinson's disease in 204 countries\/territories From 1990 to 2019","volume":"9","author":"Ou","year":"2021","journal-title":"Front Public Health"},{"key":"10.1016\/j.clinthera.2024.01.003_bib0003","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a009282","article-title":"Motor control abnormalities in Parkinson's disease","volume":"2","author":"Mazzoni","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.clinthera.2024.01.003_bib0004","first-page":"10","article-title":"Parkinson's disease: prevalence, diagnosis and impact","volume":"25","author":"Wong","year":"2014","journal-title":"Health Rep"},{"key":"10.1016\/j.clinthera.2024.01.003_bib0005","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ncl.2018.01.002","article-title":"Generalized myasthenia gravis: classification, clinical presentation, natural history, and epidemiology","volume":"36","author":"Hehir","year":"2018","journal-title":"Neurol Clin"},{"key":"10.1016\/j.clinthera.2024.01.003_bib0006","first-page":"24","article-title":"A review of disease mechanisms and current and emerging treatment options for generalized myasthenia gravis","author":"Bril","year":"2022","journal-title":"Prim Care Companion CNS Disord"},{"key":"10.1016\/j.clinthera.2024.01.003_bib0007","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1471-2377-10-46","article-title":"A systematic review of population based epidemiological studies in myasthenia gravis","volume":"10","author":"Carr","year":"2010","journal-title":"BMC Neurol"},{"key":"10.1016\/j.clinthera.2024.01.003_bib0008","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3233\/JPD-130186","article-title":"Levodopa in the treatment of Parkinson's disease: current status and new developments","volume":"3","author":"Salat","year":"2013","journal-title":"J Parkinsons Dis"},{"key":"10.1016\/j.clinthera.2024.01.003_bib0009","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/nyas.13537","article-title":"Developing treatment guidelines for myasthenia gravis","volume":"1412","author":"Sanders","year":"2018","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.clinthera.2024.01.003_bib0010","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/cei.12217","article-title":"Myasthenia gravis: an update for the clinician","volume":"175","author":"Sieb","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.clinthera.2024.01.003_bib0011","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1080\/13814788.2017.1375092","article-title":"Series: Practical guidance to qualitative research. Part 4: Trustworthiness and publishing","volume":"24","author":"Korstjens","year":"2018","journal-title":"Eur J Gen Pract"},{"key":"10.1016\/j.clinthera.2024.01.003_bib0012","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/0303-8467(93)90008-5","article-title":"Coexistence of Parkinson's disease and myasthenia gravis: a case report","volume":"95","author":"Kao","year":"1993","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.clinthera.2024.01.003_bib0013","first-page":"56","article-title":"Patients with Parkinson's disease and myasthenia gravis\u2014a report of three new cases and review of the literature","author":"Odajiu","year":"2019","journal-title":"Medicina (Kaunas)"},{"key":"10.1016\/j.clinthera.2024.01.003_bib0014","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/S0140-6736(76)93095-6","article-title":"Dopamine acetylcholine imbalance in Parkinson's disease. Possible regenerative overgrowth of cholinergic axon terminals","volume":"1","author":"Spehlmann","year":"1976","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2024.01.003_bib0015","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.parkreldis.2016.04.005","article-title":"Is it just a coincidence? Three new cases of myasthenia gravis associated with Parkinson's disease","volume":"28","author":"Sciacca","year":"2016","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.clinthera.2024.01.003_bib0016","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/ggi.12558","article-title":"Co-occurrence of myasthenia gravis with Parkinson's disease: a not to be missed diagnosis","volume":"16","author":"Tung-Chen","year":"2016","journal-title":"Geriatr Gerontol Int"},{"key":"10.1016\/j.clinthera.2024.01.003_bib0017","first-page":"4","article-title":"Parkinson disease associated with myasthenia gravis: a case reportand literature review","author":"Beyrouti","year":"2016","journal-title":"J Neurologic Disorders"},{"key":"10.1016\/j.clinthera.2024.01.003_bib0018","doi-asserted-by":"crossref","first-page":"e120","DOI":"10.1111\/jgs.14359","article-title":"Myasthenia gravis manifesting as head drop in an elderly adult with Parkinson's disease","volume":"64","author":"Aiba","year":"2016","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.clinthera.2024.01.003_bib0019","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.clinthera.2024.01.003_bib0020","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1600-0404.1988.tb03653.x","article-title":"Parkinsonism induced by pyridostigmine","volume":"78","author":"Iwasaki","year":"1988","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.clinthera.2024.01.003_bib0021","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1007\/s00415-003-1088-y","article-title":"Parkinson's disease associated with myasthenia gravis. A report of 4 cases","volume":"250","author":"Levin","year":"2003","journal-title":"J Neurol"},{"key":"10.1016\/j.clinthera.2024.01.003_bib0022","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1177\/1941874414522498","article-title":"Two cases of Parkinson disease and concurrent myasthenia gravis, generalized and ocular","volume":"4","author":"Neuman","year":"2014","journal-title":"Neurohospitalist"},{"key":"10.1016\/j.clinthera.2024.01.003_bib0023","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.jclinane.2016.05.033","article-title":"Anesthesia management in the coexistence of myasthenia gravis and parkinsonism","volume":"34","author":"Ozer","year":"2016","journal-title":"J Clin Anesth"},{"key":"10.1016\/j.clinthera.2024.01.003_bib0024","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.52768\/2766-7820\/1463","article-title":"The feasibility of physical therapy in a patient with Parkinson's disease and myasthenia gravis: a case report","volume":"2","author":"Xie","year":"2021","journal-title":"J Clin Images Med Case Rep"},{"key":"10.1016\/j.clinthera.2024.01.003_bib0025","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1212\/WNL.37.5.832","article-title":"Parkinson's disease and myasthenia gravis: adverse effect of trihexyphenidyl on neuromuscular transmission","volume":"37","author":"Ueno","year":"1987","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2024.01.003_bib0026","first-page":"185","article-title":"A case report of Parkinson's disease combined with myasthenia gravis","volume":"10","author":"Xie","year":"2003","journal-title":"Chin J Neuroimmunol & Neurol"},{"key":"10.1016\/j.clinthera.2024.01.003_bib0027","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/NRL.0b013e3182173356","article-title":"Myasthenia gravis as a cause of head drop in Parkinson disease","volume":"17","author":"Uludag","year":"2011","journal-title":"Neurologist"},{"key":"10.1016\/j.clinthera.2024.01.003_bib0028","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jns.2017.03.026","article-title":"Head drop in Parkinson's disease complicated by myasthenia gravis and myopathy","volume":"376","author":"Hogg","year":"2017","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.clinthera.2024.01.003_bib0029","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clineuro.2019.02.009","article-title":"A rare cause of axial worsening in Parkinson's disease: a case of myasthenic pseudo-parkinsonism","volume":"179","author":"Marano","year":"2019","journal-title":"Clinical Neurology and Neurosurgery"},{"key":"10.1016\/j.clinthera.2024.01.003_bib0030","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1002\/mds.22704","article-title":"Head drop in an elder Parkinson's disease after development of myasthenia gravis","volume":"24","author":"Unal-Cevik","year":"2009","journal-title":"Mov Disord"},{"key":"10.1016\/j.clinthera.2024.01.003_bib0031","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s10072-014-1660-5","article-title":"Parkinson's disease associated with myasthenia gravis and rheumatoid arthritis","volume":"35","author":"Zis","year":"2014","journal-title":"Neurol Sci"},{"key":"10.1016\/j.clinthera.2024.01.003_bib0032","first-page":"93","article-title":"Parkinson's disease and progressive dysphagia: consider myasthenia gravis","volume":"32","author":"Urban","year":"2017","journal-title":"Movement Disorders"},{"key":"10.1016\/j.clinthera.2024.01.003_bib0033","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.parkreldis.2007.02.009","article-title":"Myasthenia gravis: an unrecognized cause of head drop in Parkinson's disease","volume":"14","author":"Fasano","year":"2008","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.clinthera.2024.01.003_bib0034","first-page":"103","article-title":"[An unusual association of myasthenia gravis and Parkinsonism in a female patient with tuberculous lymphadenitis]","volume":"119","author":"Tasi\u0107","year":"1991","journal-title":"Srp Arh Celok Lek"},{"key":"10.1016\/j.clinthera.2024.01.003_bib0035","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s00115-017-0378-z","article-title":"Bei Morbus Parkinson und progredienter Dysphagie an Myasthenia gravis denken","volume":"89","author":"Urban","year":"2018","journal-title":"Der Nervenarzt"},{"key":"10.1016\/j.clinthera.2024.01.003_bib0036","first-page":"13","article-title":"Prescribing cascade. A proposed new way to evaluate it","volume":"77","author":"Ponte","year":"2017","journal-title":"Medicina (B Aires),"},{"key":"10.1016\/j.clinthera.2024.01.003_bib0037","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/jgs.15767","article-title":"2019 Updated AGS Beers Criteria\u00ae for Potentially Inappropriate Medication Use in Older Adults","volume":"67","year":"2019","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.clinthera.2024.01.003_bib0038","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/mds.21244","article-title":"Evidence-based analysis of physical therapy in Parkinson's disease with recommendations for practice and research","volume":"22","author":"Keus","year":"2007","journal-title":"Mov Disord"},{"key":"10.1016\/j.clinthera.2024.01.003_bib0039","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1177\/1545968320952799","article-title":"Physiotherapy in Parkinson's disease: a meta-analysis of present treatment modalities","volume":"34","author":"Radder","year":"2020","journal-title":"Neurorehabil Neural Repair"},{"key":"10.1016\/j.clinthera.2024.01.003_bib0040","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1080\/00207454.2016.1275617","article-title":"Physical therapy and occupational therapy in Parkinson's disease","volume":"127","author":"Radder","year":"2017","journal-title":"Int J Neurosci"},{"key":"10.1016\/j.clinthera.2024.01.003_bib0041","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1055\/s-0041-1725133","article-title":"Evidence for early and regular physical therapy and exercise in Parkinson's disease","volume":"41","author":"Ellis","year":"2021","journal-title":"Semin Neurol"},{"key":"10.1016\/j.clinthera.2024.01.003_bib0042","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/nrneurol.2017.128","article-title":"Long-term effects of exercise and physical therapy in people with Parkinson disease","volume":"13","author":"Mak","year":"2017","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.clinthera.2024.01.003_bib0043","first-page":"5","article-title":"Evidence-based practice in rehabilitation of myasthenia gravis. A systematic review of the literature","author":"Corrado","year":"2020","journal-title":"J Funct Morphol Kinesiol"},{"key":"10.1016\/j.clinthera.2024.01.003_bib0044","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1002\/mus.25552","article-title":"Exercise in myasthenia gravis: a feasibility study of aerobic and resistance training","volume":"56","author":"Rahbek","year":"2017","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.clinthera.2024.01.003_bib0045","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.nmd.2021.05.007","article-title":"Fatigue, physical activity and associated factors in 779 patients with myasthenia gravis","volume":"31","author":"Andersen","year":"2021","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.clinthera.2024.01.003_bib0046","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/WCO.0000000000000579","article-title":"Update in therapeutic strategies for Parkinson's disease","volume":"31","author":"Kulisevsky","year":"2018","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.clinthera.2024.01.003_bib0047","doi-asserted-by":"crossref","first-page":"88","DOI":"10.2174\/1871524920666200705222842","article-title":"Understanding the pathogenesis involved in Parkinson's disease and potential therapeutic treatment strategies","volume":"20","author":"Dhanawat","year":"2020","journal-title":"Cent Nerv Syst Agents Med Chem"},{"key":"10.1016\/j.clinthera.2024.01.003_bib0048","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1080\/09638288.2018.1528634","article-title":"Inter-professional communication and interaction in the neurological rehabilitation team: a literature review","volume":"42","author":"Franz","year":"2020","journal-title":"Disabil Rehabil"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291824000146?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291824000146?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T06:21:39Z","timestamp":1712730099000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291824000146"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S0149291824000146"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2024.01.003","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic Effect and Side Effects of Pharmacotherapy in Patients With Parkinson Disease and Myasthenia Gravis: A Systematic Review of Case Reports and Case Series Studies","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2024.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}